Challenges in reducing group B Streptococcus disease in African settings

Area of Science:

• Neonatal health
• Infectious diseases
• Public health

Background:

• Group B Streptococcus (GBS) is a major cause of neonatal sepsis and meningitis, particularly in high-income countries.
• Evidence indicates a substantial GBS disease burden in resource-limited settings, necessitating practical prevention strategies.
• Current prevention methods like intrapartum antibiotic prophylaxis (IAP) face challenges in sub-Saharan Africa.

Purpose of the Study:

• To review current evidence on reducing invasive GBS disease in African settings.
• To discuss the development status of GBS vaccines.
• To assess the practical implementation of GBS preventative measures in Africa.

Main Methods:

• Literature review of GBS disease burden, prevention strategies, and vaccine development.
• Analysis of the applicability of existing GBS prevention methods in sub-Saharan Africa.
• Exploration of challenges and opportunities for GBS disease control in resource-limited environments.

Main Results:

• Intrapartum antibiotic prophylaxis (IAP) has reduced early-onset GBS disease in North America and Europe but presents implementation challenges in Africa.
• Late-onset GBS disease prevention remains complex and controversial.
• GBS vaccines are in late-stage development (Phase III trials), offering future prevention potential.

Conclusions:

• There is a critical need for practical and effective strategies to reduce GBS disease burden in African neonates.
• GBS vaccine development holds promise but requires further assessment for widespread implementation.
• Adapting and implementing preventative measures against GBS disease in sub-Saharan Africa requires tailored approaches.